This review article summarizes recent applications of electrochemical techniques to redox-active drug development and mechanistic studies. It includes a general introduction to the use of electrochemistry in biology, with a focus on how electrochemistry can uniquely provide both kinetic and thermodynamic information. A number of studies are reported from the literature and the authors’ laboratories, including the investigation of reactive oxygen species, biooxidative/bioreductive activation of pro-drugs, and DNA alkylation, with a particular emphasis on quinones and related compounds. Data from techniques ranging from traditional cyclic voltammetry to sophisticated single cell studies are presented. The examples herein presented illustrate how electrochemical, biochemical and medical knowledge can be integrated to develop strategies for the design and development of redox-selective therapeutics.

The selective oestrogen receptor modulator tamoxifen is a leading agent in the adjuvant treatment of breast cancer. Several organometallic moieties have been vectorised with tamoxifen, in order to improve on the latter's antiproliferative properties by the addition of a potentially cytotoxic moiety, and have been evaluated versus both oestrogen receptor positive (MCF7) and oestrogen receptor negative (MDA-MB231) breast cancer cells. For tamoxifen analogues with ((R,R)-trans-1,2-diaminocyclohexane)platinum(II), cyclopentadienyl rhenium tricarbonyl, and ruthenocene tethers, there was no enhancement of the antiproliferative effect on oestrogen receptor positive cells, nor any cytotoxic effect on oestrogen receptor negative cells, while those containing cyclopentadienyl titanium dichloride showed an oestrogenic effect. However, compounds where ferrocene replaces tamoxifen's phenyl ring were strongly cytotoxic against both cell lines. The synthesis and biological results of these compounds is reviewed and placed in the historic context of inorganic compounds in therapy.